EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E

Eric X Chen, Petr Kavan, Mustapha Tehfe, Jeremy S Kortmansky, Michael B Sawyer, E Gabriela Chiorean, Christopher H Lieu, Blase Polite, Lucas Wong, Marwan Fakih, Kristen Spencer, Jorge Chaves und 4 weitere

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.03.002 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Eric X Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada. Electronic address: eric.chen@uhn.ca. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized, Benzimidazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cohorts A, C, and E of the phase Ib KEYNOTE-651 study evaluated pembrolizumab + binimetinib ± chemotherapy in microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. PATIENTS AND METHODS: Patients received pembrolizumab 200 mg every 3 weeks plus binimetinib 30 mg twice daily alone (cohort A; previously treated with any chemotherapy) or with 5-fluorouracil, leucovorin, oxaliplatin (cohort C; previously untreated) or 5-fluorouracil, leucovorin, irinotecan (cohort E; previously treated with 1 line of therapy including fluoropyrimidine + oxaliplatin-based regimen) every 2 weeks. Binimetinib dose-escalation to 45 mg twice daily was planned in all cohorts using a modified toxicity probability interval design (target dose-limiting toxicity [DLT], 30%). The primary endpoint was safety; investigator-assessed objective response rate was secondary. RESULTS: In cohort A, 1/6 patients (17%) had DLTs with binimetinib 30 mg; none occurred in 14 patients with 45 mg. In cohort C, 3/9 patients (33%) had DLTs with binimetinib 30 mg; dose was not escalated to 45 mg. In cohort E, 1/5 patients (20%) had DLTs with binimetinib 30 mg; 5/10 patients (50%) had DLTs with 45 mg. Enrollment was stopped in cohort E binimetinib 45 mg and deescalated to 30 mg; 2/4 additional patients (50%) had DLTs with binimetinib 30 mg (total 3/9 [33%] had DLTs with binimetinib 30 mg). Objective response rate was 0% in cohort A, 9% in cohort C, and 15% in cohort E. CONCLUSION: Per DLT criteria, binimetinib + pembrolizumab (cohort A) was tolerable, binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, oxaliplatin (cohort C) did not qualify for binimetinib dose escalation to 45 mg, and binimetinib + pembrolizumab + 5-fluorouracil, leucovorin, irinotecan (cohort E) required binimetinib dose reduction from 45 to 30 mg. No new safety findings were observed across cohorts. There was no apparent additive efficacy when binimetinib + pembrolizumab was added to chemotherapy. Data did not support continued enrollment in cohorts C and E.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsAntibodies, Monoclonal, HumanizedBenzimidazolesHumansFemaleMaleMiddle AgedAgedAdultFluorouracilIrinotecanOxaliplatinDNA Mismatch RepairLeucovorinMicrosatellite InstabilityAged, 80 and over

Stichwörter der Autor:innen

BinimetinibColorectal cancerMicrosatellite stableMismatch repair-proficientPembrolizumab

Substanzen

binimetinibAntibodies, Monoclonal, HumanizedpembrolizumabBenzimidazolesFluorouracilIrinotecanOxaliplatinLeucovorin

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2C1, Canada. Electronic address: eric.chen@uhn.ca.
  • Department of Medicine and Oncology, Sir Mortimer B. Davis Jewish General Hospital, Segal Cancer Centre, McGill University, Montreal, QC H3T 1E2, Canada.
  • Hematology and Medical Oncology Division, Centre Hospitalier Universitaire de Montreal, University of Montreal, Montreal, QC H2X 0C1, Canada.
  • Section of Medical Oncology, Yale Cancer Center, New Haven, CT.
  • Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
  • Division of Medical Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Clinical Research Division, Seattle, WA.

Zitieren

APA

Chen, E. X., Kavan, P., Tehfe, M., Kortmansky, J. S., Sawyer, M. B., Chiorean, E. G., Lieu, C. H., Polite, B., Wong, L., Fakih, M., Spencer, K., Chaves, J., Li, C., Leconte, P., Adelberg, D., & Kim, R. (2024). Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.03.002

Vancouver

Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, Chiorean EG, et al. Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.03.002

BibTeX
@article{Chen2024,
  author = {Chen, Eric X and Kavan, Petr and Tehfe, Mustapha and Kortmansky, Jeremy S and Sawyer, Michael B and Chiorean, E Gabriela and Lieu, Christopher H and Polite, Blase and Wong, Lucas and Fakih, Marwan and Spencer, Kristen and Chaves, Jorge and Li, Chenxiang and Leconte, Pierre and Adelberg, David and Kim, Richard},
  title = {Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.03.002}
}
Kostenlos starten →